BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Company Overview - BiomX Inc. is a clinical-stage company focused on developing novel natural and engineered phage therapies targeting specific pathogenic bacteria [1][3] - The company utilizes its BOLT ("BacteriOphage Lead to Treatment") platform to customize phage compositions against proprietary bacterial targets [3] Financial Results Announcement - BiomX will report its fourth quarter and full year 2024 financial results on March 25, 2025 [1] - A press release with the results will be available in the Investors section of the company's website [2] - The company plans to host a conference call and live audio webcast to discuss the financial results and initial topline results from its Phase 2 trial for diabetic foot osteomyelitis [2]